@article{7790,
  keywords = {Chemistry Techniques, Analytical, Humans, Hydrolysis, Immunosuppressive Agents, Models, Chemical, Molecular Structure, Stereoisomerism, Thalidomide},
  author = {Bosch E and Sánchez R and Rojas SF and Ojeda BC},
  title = {Recent advances in analytical determination of thalidomide and its metabolites.},
  abstract = {<p>Thalidomide, a racemate, is coming into clinical use as immuno-modulating and anti-inflammatory drug. Thalidomide was approved by the FDA in July 1998 for the treatment of erythema nodusum leprosum associated with leprosy. Recently, thalidomide is proving to be a promising drug in the treatment of a number of cancers and inflammatory diseases, such as multiple myeloma, inflammatory bowel disease (Crohn's disease), HIV and cancer associated cachexia. These effects may chiefly be exerted by S-thalidomide, but the enantiomers are inter-converted in vivo. Thalidomide is given orally, although parenteral administration would be desirable in some clinical situations. Thalidomide has been determined in formulations and, principally in biological fluids by a variety of methods such as high-performance liquid chromatography with ultraviolet detection and liquid chromatography coupled with tandem mass spectrometry. The overview includes the most relevant analytical methodologies used in its determination.</p>},
  year = {2008},
  journal = {Journal of pharmaceutical and biomedical analysis},
  volume = {46},
  pages = {9-17},
  month = {2008 Jan 07},
  issn = {0731-7085},
  doi = {10.1016/j.jpba.2007.10.003},
  language = {eng},
}